智通财经APP获悉，和铂医药-B(02142)涨超3%，截至发稿，涨1.85%，报12.18港元，成交额1403.89万 港元。 值得关注的是，近日，和铂医药-B介绍AI智药业务的最近进展情况。此前，公司曾推出Hu-mAtrIx™人 工智能平台，并在此基础上建立了首个全人源AI HCAb模型——全人源重链抗体(HCAb)生成和筛选模 型。和铂医药-B将AI智药提升到战略意义层面的高度，打造整合抗体工程、AI辅助药物发现、自动化 湿实验室三位一体的A3大分子创新药物研发平台，干湿结合以实现AI智药的真实落地场景，海量湿实 验数据反哺AI模型实现高质量训练的正反馈循环。 消息面上，1月29日，和铂医药-B发布公告，根据公司股东于公司2025年6月11日举行的股东周年大会上 批准的购回股份的一般授权及(如适用)未来股东于公司不时的股东大会上批准的购回股份的任何一般授 权，其拟不时于公开市场上购回价值不超过3亿港元的公司股份。 ...

值得关注的是，近日，和铂医药-B介绍AI智药业务的最近进展情况。此前，公司曾推出Hu-mAtrIx人工 智能平台，并在此基础上建立了首个全人源AI HCAb模型——全人源重链抗体(HCAb)生成和筛选模 型。和铂医药-B将AI智药提升到战略意义层面的高度，打造整合抗体工程、AI辅助药物发现、自动化 湿实验室三位一体的A3大分子创新药物研发平台，干湿结合以实现AI智药的真实落地场景，海量湿实 验数据反哺AI模型实现高质量训练的正反馈循环。 消息面上，1月29日，和铂医药-B发布公告，根据公司股东于公司2025年6月11日举行的股东周年大会上 批准的购回股份的一般授权及(如适用)未来股东于公司不时的股东大会上批准的购回股份的任何一般授 权，其拟不时于公开市场上购回价值不超过3亿港元的公司股份。 和铂医药-B(02142)涨超3%，截至发稿，涨1.85%，报12.18港元，成交额1403.89万港元。 ...

Core Viewpoint - The collaboration between Harbour BioMed and Bristol-Myers Squibb marks a significant step in advancing next-generation bispecific antibody therapies, with potential payments exceeding $1.1 billion for Harbour BioMed [2][3]. Group 1: Strategic Collaboration - Harbour BioMed has entered a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb to co-develop next-generation bispecific antibody therapies [1][2]. - The agreement includes an initial payment of $90 million, with potential milestone payments of up to $1.035 billion, plus tiered royalties based on future product net sales [2][3]. Group 2: Technological Advancements - The collaboration will leverage Harbour BioMed's Harbour Mice fully human antibody technology platform, which is capable of efficiently discovering and developing innovative biotherapies [2][3]. - Harbour Mice can generate fully human monoclonal antibodies in various formats, including dual heavy and light chains (H2L2) and heavy chain-only (HCAb) antibodies, enhancing anti-tumor efficacy beyond traditional therapies [3]. Group 3: AI Integration - Harbour BioMed is integrating AI technology into its drug discovery processes, exemplified by the launch of its AI-assisted drug discovery engine, Hu-mAtrIx, which aims to accelerate antibody discovery across multiple therapeutic areas [4]. - The Hu-mAtrIx platform has been designed to work seamlessly with the Harbour Mice technology, utilizing advanced AI models for sequence generation and drugability prediction [4]. Group 4: Global Ecosystem Development - Harbour BioMed has established collaborations with multiple multinational pharmaceutical companies, including AstraZeneca, Pfizer, and Moderna, with total agreements exceeding $10 billion [6][7]. - The company employs diverse collaboration models, including licensing agreements and joint ventures, to enhance its global ecosystem for antibody drug development [7]. Group 5: Future Goals - Harbour BioMed aims to become a "new infrastructure" for global antibody drug development within the next two years, driven by its technological advancements and collaborative efforts [4].

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo [1] Group 1: Strategic Partnership - Heptagon Pharmaceuticals and Evinova announced a strategic cooperation to leverage AI and digital technologies to enhance the efficiency of innovative biotherapy development [1] - The partnership aims to build an AI-driven open ecosystem for drug research and development by utilizing each company's strengths [1] Group 2: AI Platform Development - Heptagon Pharmaceuticals launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ AI platform during a global R&D day event in Shanghai [1] - The model is based on proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, the platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo to enhance the efficiency of innovative biotherapy development through AI and digital technologies [1] Group 1 - Heptagon Pharmaceuticals and Evinova will leverage their respective strengths to build an AI-driven open ecosystem for drug development [1] - The company recently launched its first fully human AIHCAb model driven by the Hu-mAtrIx AI platform during a global R&D day event in Shanghai [1] - The AIHCAb model is based on proprietary HarbourMice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] Group 2 - The platform differs from traditional screening methods by achieving a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Core Viewpoint - The article highlights the successful launch of the AI-driven HCAb model by Heptares Therapeutics, which is expected to revolutionize the development of next-generation therapeutic antibodies and enhance drug discovery processes [1] Company Developments - Heptares Therapeutics' stock rose over 4%, currently trading at 13.49 HKD with a transaction volume of 52.54 million HKD [1] - The company hosted the "Zhi Yao He Po Hui Chuang Xing Chen" Global R&D Day in Shanghai on October 28, where it unveiled its first fully human AI HCAb model [1] Technology and Innovation - The AI HCAb model is based on Heptares' proprietary Harbour Mice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] - This platform establishes a closed-loop process that combines AI design, intelligent screening, and wet lab validation, differentiating it from traditional screening methods [1] Market Implications - The AI HCAb model is anticipated to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - Heptares aims to reshape the landscape of biopharmaceutical development by leveraging AI capabilities and HCAb technology to address unmet clinical needs through data-driven predictive processes [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has launched its first fully human AI HCAb model driven by the Hu-mAtrIx™ AI platform, aiming to revolutionize the development of biopharmaceuticals through advanced AI capabilities [1] Group 1: Company Developments - HAPO Pharmaceuticals experienced a stock increase of over 4%, with a current price of 13.49 HKD and a trading volume of 52.54 million HKD [1] - The company successfully held the "Zhiyao HAPO Huichuang Xingchen" global R&D day event in Shanghai on October 28, where the new AI-driven model was officially announced [1] - The AI HCAb model is based on proprietary Harbour Mice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] Group 2: Industry Implications - The AI HCAb model is expected to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - The platform aims to reshape the landscape of biopharmaceutical development by creating a closed-loop process that combines AI design, intelligent screening, and wet lab validation [1] - HAPO Pharmaceuticals is leveraging AI capabilities and HCAb technology to expedite the implementation of innovative therapies and identify unmet clinical needs through data-driven predictive processes [1]